Form 4: Bristol Myers Squibb Director's Stock Unit Transactions

Theodore R. Samuels II, a Director at Bristol Myers Squibb, reported transactions involving deferred share units.

Summary

• Theodore R. Samuels II, a Director at Bristol Myers Squibb, has reported transactions related to deferred share units.
• These deferred share units are set to convert into shares of common stock upon settlement.
• Settlement occurs when the reporting person ceases to be a director or at a previously specified future date.
• The filing indicates a transaction date of June 30, 2026, with 889.448 deferred share units acquired.
• The value associated with these units is $57.62 per unit, totaling 70,360.664 units beneficially owned after the transaction.
• This ownership includes deferred compensation and reinvested dividends under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a routine disclosure of director stock unit transactions rather than a significant event impacting company performance or strategy.

Positives

• Director Samuels continues to hold deferred share units, indicating ongoing commitment and participation in the company's long-term incentive plans.
• The deferred compensation plan and dividend reinvestment suggest a mechanism for increasing beneficial ownership over time.

Negatives

• The filing does not contain any negative financial results or operational setbacks.

Risks

• The value of the deferred share units is subject to market fluctuations and the future performance of Bristol Myers Squibb stock.
• The settlement of these units is contingent upon the reporting person's tenure as a director or a pre-determined future date, introducing timing-related uncertainties.

Future Outlook

The deferred share units are scheduled to convert into common stock upon settlement, which will occur either when the reporting person ceases to be a director or at a future date previously specified by the reporting person. The value of these units is tied to the future performance of Bristol Myers Squibb's common stock.

Management Comments

• Theodore R. Samuels II, Director, has reported these transactions.
• The filing is signed by Amy Fallone, attorney-in-fact for Theodore R. Samuels.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions in the pharmaceutical and biotechnology sector, providing transparency on executive and director holdings. These transactions often reflect long-term incentive structures and personal investment strategies within the industry.

Stakeholder Impact

• Shareholders gain transparency into director's beneficial ownership and potential future shareholding.
• Directors' compensation structures are highlighted, showing alignment with long-term company value.

Next Steps

• Deferred share units will convert to common stock upon settlement.
• Settlement will occur upon the reporting person ceasing to be a director or at a specified future date.

Key Dates

Keywords

Bristol Myers Squibb, BMY, Form 4, SEC Filing, Director, Deferred Share Units, Beneficial Ownership, Stock Options, Insider Trading, Executive Compensation, 10b5-1 Plan